TAPISTRY

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

7 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The purpose of this study is to evaluate the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body's immune system fight cancer cells) in patients who have solid tumors with specific genetic alterations or with a high number of mutations. Patients will be assigned to cohorts (groups) based on having a specific type of genetic alteration in their tumor. The study includes cohorts for patients whose tumors have genetic alterations in the ROS1, NTRK, PIK3CA, BRAF, or RET genes or a high number of mutations in their tumor.

Eligibility & Criteria

IRB #:
20-018211
Official Title:
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Study Phase:
Phase II
Eligible Age Range:
0 - 25 Years
Gender:
All
Study Categories:

Visit Criteria

This study will enroll patients with advanced solid tumors that have one of the genetic alterations listed above. You will receive one of several investigational targeted therapies or receive immunotherapy with atezolizumab (a drug that helps the immune system fight cancer cells) based on your tumor's genetic alteration.

Participants will frequently come to CHOP Philadelphia for assessments as part of regular oncology care. This includes follow-up visits, blood draws, and scans.

Additional procedures may include:

  • Tumor tissue submission
  • ECG (electrocardiogram) 
  • Blood samples
  • Diaries
  • Questionnaires
  • Genetic biomarker testing to better understand the cancer

Treatment may continue until disease progression (tumor growth), unacceptable side effects, or you or your physician choose to discontinue.

Leader
Theodore W. Laetsch

Theodore Laetsch, MD